Efferent Labs Signs Agreement With Evotec to Continue Development of Groundbreaking Medical Diagnostic Product

Efferent Labs, Inc., a developer of high-value medical technology and devices, is pleased to announce that it has entered into a multi-year agreement with Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) for the continued development of Efferent’s CytoComm Living Biosensor System.

Under the agreement, Efferent will work with Evotec to further develop and validate the CytoComm Living Biosensor System.